Literature DB >> 18565502

Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia.

Hai Yan Zhang1, Chun Yan Zheng, Han Yan, Zhi Fei Wang, Li Li Tang, Xin Gao, Xi Can Tang.   

Abstract

Huperzine A (HupA), a novel Lycopodium alkaloid isolated from Chinese folk medicine Huperzia serrata (Qian Ceng Ta), is a potent, selective and well-tolerated inhibitor of acetylcholinesterase (AChE). It has been proven to significantly improve the learning and memory impairment in Alzheimer's disease (AD) and vascular dementia (VaD) patients in China. Interestingly, our recent data indicate that HupA also possesses other protective functions. This paper will give an overview on the protective effects of HupA, which includes regulating beta-amyloid precursor protein (APP) metabolism, protecting against Abeta-mediated oxidative stress, apoptosis and mitochondrial dysfunction, as well as anti-inflammation. The multiple neuroprotective effects of HupA might yield additional beneficial effects in AD and VaD therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565502     DOI: 10.1016/j.cbi.2008.04.049

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  18 in total

1.  The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3β pathway mediates bilobalide-induced reduction in amyloid β-peptide.

Authors:  Chun Shi; Dong-dan Zheng; Feng-ming Wu; Jun Liu; Jie Xu
Journal:  Neurochem Res       Date:  2011-09-28       Impact factor: 3.996

2.  Neuroprotective effects of Tongmai Yizhi Decoction () against Alzheimer's disease through attenuating cyclin-dependent kinase-5 expression.

Authors:  Jing-Han Feng; Bao-Chang Cai; Wei-Feng Guo; Ming-Yan Wang; Yong Ma; Qiao-Xi Lu
Journal:  Chin J Integr Med       Date:  2016-07-09       Impact factor: 1.978

3.  Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model.

Authors:  Chun-Yan Wang; Wei Zheng; Tao Wang; Jing-Wei Xie; Si-Ling Wang; Bao-Lu Zhao; Wei-Ping Teng; Zhan-You Wang
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

Review 4.  Huperzine A for mild cognitive impairment.

Authors:  Jirong Yue; Bi Rong Dong; Xiufang Lin; Ming Yang; Hong Mei Wu; Taixiang Wu
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

5.  The effects of two-stage carotid occlusion on spatial memory and pro-inflammatory markers in the hippocampus of rats.

Authors:  Mehrnoush Moghaddasi; Majid Taati; Payman Asadian; Ali Reza Khalatbary; Raheleh Asaei; Naser Pajouhi
Journal:  J Physiol Sci       Date:  2016-07-28       Impact factor: 2.781

Review 6.  Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice.

Authors:  Chun Shi; Jun Liu; Fengming Wu; David T Yew
Journal:  Int J Mol Sci       Date:  2010-01-08       Impact factor: 5.923

7.  Acetylcholinesterase-independent protective effects of huperzine A against iron overload-induced oxidative damage and aberrant iron metabolism signaling in rat cortical neurons.

Authors:  Ling-Xue Tao; Xiao-Tian Huang; Yu-Ting Chen; Xi-Can Tang; Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-08-08       Impact factor: 6.150

8.  Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.

Authors:  Bai-Song Wang; Hao Wang; Zhao-Hui Wei; Yan-Yan Song; Lu Zhang; Hong-Zhuan Chen
Journal:  J Neural Transm (Vienna)       Date:  2009-02-17       Impact factor: 3.575

9.  New perspectives on chinese herbal medicine (zhong-yao) research and development.

Authors:  Si-Yuan Pan; Si-Bao Chen; Hong-Guang Dong; Zhi-Ling Yu; Ji-Cui Dong; Zhi-Xian Long; Wang-Fun Fong; Yi-Fan Han; Kam-Ming Ko
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-10       Impact factor: 2.629

10.  New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.

Authors:  Si-Yuan Pan; Shu-Feng Zhou; Si-Hua Gao; Zhi-Ling Yu; Shuo-Feng Zhang; Min-Ke Tang; Jian-Ning Sun; Dik-Lung Ma; Yi-Fan Han; Wang-Fun Fong; Kam-Ming Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.